Glaukos (NYSE:GKOS) PT Raised to $100.00 at Mizuho

Glaukos (NYSE:GKOS) had its target price raised by analysts at Mizuho from $85.00 to $100.00 in a research report issued on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the medical instruments supplier’s stock. Mizuho’s price objective would suggest a potential upside of 0.29% from the stock’s current price.

Several other analysts have also issued reports on the stock. Citigroup lifted their target price on shares of Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Piper Sandler raised their price target on shares of Glaukos from $90.00 to $105.00 and gave the stock an “overweight” rating in a research note on Friday, December 22nd. StockNews.com downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. Needham & Company LLC raised their price target on shares of Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $110.00 price target on shares of Glaukos in a research note on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus target price of $99.80.

Glaukos Stock Down 1.6 %

GKOS stock opened at $99.71 on Thursday. The firm has a market cap of $4.93 billion, a PE ratio of -35.87 and a beta of 1.08. The company has a debt-to-equity ratio of 0.77, a quick ratio of 4.78 and a current ratio of 5.34. The firm’s fifty day moving average is $91.38 and its 200 day moving average is $79.70. Glaukos has a one year low of $45.38 and a one year high of $102.33.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.07). Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The company had revenue of $82.40 million during the quarter, compared to analyst estimates of $81.00 million. During the same quarter last year, the business earned ($0.53) EPS. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. On average, research analysts forecast that Glaukos will post -2.18 EPS for the current year.

Insider Buying and Selling at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 583 shares of Glaukos stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $90.54, for a total transaction of $52,784.82. Following the completion of the sale, the chief financial officer now directly owns 54,618 shares in the company, valued at $4,945,113.72. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, COO Joseph E. Gilliam sold 140,245 shares of Glaukos stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $92.14, for a total value of $12,922,174.30. Following the completion of the transaction, the chief operating officer now owns 98,388 shares in the company, valued at $9,065,470.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alex R. Thurman sold 583 shares of Glaukos stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $90.54, for a total transaction of $52,784.82. Following the completion of the transaction, the chief financial officer now owns 54,618 shares of the company’s stock, valued at approximately $4,945,113.72. The disclosure for this sale can be found here. Insiders sold a total of 248,464 shares of company stock worth $23,405,250 over the last three months. Insiders own 7.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GKOS. Bank of New York Mellon Corp grew its holdings in shares of Glaukos by 0.6% in the first quarter. Bank of New York Mellon Corp now owns 481,228 shares of the medical instruments supplier’s stock valued at $27,825,000 after purchasing an additional 2,843 shares in the last quarter. HighTower Advisors LLC acquired a new position in Glaukos during the 1st quarter worth approximately $208,000. Natixis Advisors L.P. acquired a new position in Glaukos during the 1st quarter worth approximately $674,000. Bank of Montreal Can grew its holdings in Glaukos by 14.2% during the 1st quarter. Bank of Montreal Can now owns 20,031 shares of the medical instruments supplier’s stock worth $1,164,000 after acquiring an additional 2,485 shares in the last quarter. Finally, MetLife Investment Management LLC grew its holdings in Glaukos by 54.8% during the 1st quarter. MetLife Investment Management LLC now owns 25,057 shares of the medical instruments supplier’s stock worth $1,449,000 after acquiring an additional 8,866 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.